GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GreenLight Biosciences Holdings PBC (NAS:GRNA) » Definitions » Financial Strength

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Financial Strength : 2 (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GreenLight Biosciences Holdings PBC Financial Strength?

GreenLight Biosciences Holdings PBC has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

GreenLight Biosciences Holdings PBC displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GreenLight Biosciences Holdings PBC did not have earnings to cover the interest expense. GreenLight Biosciences Holdings PBC's debt to revenue ratio for the quarter that ended in Mar. 2023 was 5.07. As of today, GreenLight Biosciences Holdings PBC's Altman Z-Score is -9.49.


Competitive Comparison of GreenLight Biosciences Holdings PBC's Financial Strength

For the Biotechnology subindustry, GreenLight Biosciences Holdings PBC's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GreenLight Biosciences Holdings PBC's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GreenLight Biosciences Holdings PBC's Financial Strength distribution charts can be found below:

* The bar in red indicates where GreenLight Biosciences Holdings PBC's Financial Strength falls into.



GreenLight Biosciences Holdings PBC Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

GreenLight Biosciences Holdings PBC's Interest Expense for the months ended in Mar. 2023 was $-1.01 Mil. Its Operating Income for the months ended in Mar. 2023 was $-28.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $59.56 Mil.

GreenLight Biosciences Holdings PBC's Interest Coverage for the quarter that ended in Mar. 2023 is

GreenLight Biosciences Holdings PBC did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

GreenLight Biosciences Holdings PBC's Debt to Revenue Ratio for the quarter that ended in Mar. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(17.865 + 59.56) / 15.28
=5.07

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

GreenLight Biosciences Holdings PBC has a Z-score of -9.49, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -9.49 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GreenLight Biosciences Holdings PBC  (NAS:GRNA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

GreenLight Biosciences Holdings PBC has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


GreenLight Biosciences Holdings PBC Financial Strength Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
GreenLight Biosciences Holdings PBC is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.
Executives
Deval L Patrick other: See Remarks BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Dennis A. Clarke other: Member of 13D group owning 10% 6 FERNWAY TERRACE, WINCHESTER MA 01890
Cummings Foundation, Inc. other: Member of 13D group owning 10% 200 WEST CUMMINGS PARK, WOBURN MA 01801
Eric Senior Anderson other: Member of 13D group owning 10% 25 N HILL ROAD, WESTOVER MA 01886
Mls Capital Fund Ii Lp other: See remarks C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105
Chelt Trading Ltd other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Highview Trust other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Montealegre Lacayo Jaime Javier other: Member of 13D Group APARTADO 15-1250, ESCAZU G2
Furneaux Capital Holdco, Llc other: Member of 13D group 1 MARINA PARK DRIVE, BOSTON MA 02210
Lewis & Clark Plant Sciences Fund I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Lewis & Clark Ventures I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Matthew Allen Walker director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Martha Schlicher director C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Marta Ortega-valle other: Member of 10% owner group C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Builders Vision, Llc 10 percent owner 110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Headlines

From GuruFocus

GreenLight Biosciences Releases Inaugural Sustainability Report

By sperokesalga sperokesalga 04-12-2023